Increasing entry of the elderly into cancer clinical trials: difficult, but unquestionably necessary.

@article{Markman2007IncreasingEO,
  title={Increasing entry of the elderly into cancer clinical trials: difficult, but unquestionably necessary.},
  author={Maurie Markman},
  journal={Oncology},
  year={2007},
  volume={72 1-2},
  pages={
          2-3
        }
}
But just how important a clinical issue is the fact the elderly are underrepresented in these trials? Does this current state of affairs genuinely compromise our ability to deliver optimal care to this patient population? As, in general, malignancy is a condition strongly associated with aging, with higher rates for the more common cancers observed in older individuals, it is increasingly clear that it is the elderly who bear the greatest malignancy-associated burden, both in terms of the… CONTINUE READING

Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-8 OF 8 REFERENCES

Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005

Participation of patients 65 years of age or older in cancer clinical trials.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003

Compar - ison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non - Hodgkin ’ s lymphoma using CHOP versus CNOP chemotherapy

P Sonneveld, M deRidder, +6 authors B Lowenberg
  • J Clin Oncol
  • 1995